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UTILIZING PERIPHERAL BLOOD CD34 COUNT AS A PREDICTOR FOR THE
NEED FOR PLERIXAFOR IN AUTOLOGOUS STEM CELL MOBILIZATION –
SINGLE INSTITUTION EXPERIENCE
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Background: Mobilization and collection of sufficient autologous he-
matopoietic stem cells (AHSC) is crucial for success of autologous stem
cell transplantation. Moncada et al. reported 14% of patients receiving
chemotherapy and GCSF for AHSC donation fail to mobilize enough
AHSC for transplant (Transfusion 43:495ff, 2003). Plerixafor 1 GCSF
resulted in 3-fold higher rate of patients achieving the targeted CD34
count in fewer AHSC collections (DiPersio et al. Blood 110:601ff,
2007). Plerixafor use in all patients is unnecessary and unlikely cost-ef-
fective. At UIHC (chemo-mobilized patients were excluded from this
analysis), all patients undergoing AHSC collection receive GCSF daily
for 5 d prior to leukapheresis. Peripheral bloodCD34 (PBCD34) count
on themorningofday4 isobtained. If thePBCD34#8/mL,plerixafor is
administered that evening followed byGCSF the nextmorning (P1G),
however if the PBCD34 count is. 8, AHSC collection proceeds with-
out plerixafor (G). The goal of this study is to evaluate our current prac-
tice in utilizing PBCD34 as a predictor of the need for plerixafor.
Methods/Results:We retrospectively reviewed data on patients mo-
bilized at UIHC for AHSC collections following the implementation
of the previous algorithm between Jan 2009 & Aug 2010. 78 patients
were analyzed: 32 in the P1G group and 46 in the G group. Patients’
characteristics are displayed inTable 1. Almost all patients in the P1G
group (30/32) had undetectable PBCD34 on d 4 (2 patients had
PBCD34 of 3 and 8/mL), compared to a median of 24/[sup]m[/sup]L
(mean 31.5, SD 17.95) in the G group (p \ 0.0001). All patients
reached their targets in # 3 collections. No mobilization failures oc-
curred. There was no significant difference in the number of collec-
tions (p 5 0.32) or in the final product CD34 counts between the
two groups (p 5 0.15) (P1G mean 8.2*106 1/-5.0, G mean 6.6*106
1/-5.5). More than 2/3 of the patients in P1G group (n 5 22,
68.8%) reached their CD34 target on first day of collection compared
to 56.5% (n 5 26) from G group (p 5 0.14). (P1G mean 7.3*106
1/-5.6, Gmean 5.4*1061/-5.6). In the P1Ggroup 5 patients needed
2 collections and 5 patients needed 3 collections to reach their target
compared to 14 and 6 in the G group respectively.
Conclusion: Despite unmeasurably low PBCD34 count in the pe-
ripheral blood the day prior to AHSC collection, plerixafor permit-
ted these patients to collect at least as well as patients with. 8 cells/
mL, usually in a single session.
Table 1. Patients’ Characteristics
P+G group G group
(n532) (n546) p-valueAge (Median, Mean, SD) 60, 55.8, 13.7 56, 51.6, 13.2 0.18
Gender (Male:Female) 14:18 26:20 0.27
Diagnosis:
Multiple Myeloma (42%) 15 18 0.64
Hodgkin Lymphooma (18%) 4 10 0.37
Non Hodgkin Lymphoma (40%) 13 18 1
Prior Therapy: 0.88
Chemotherapy only 26 38
Chemotherapy and Radiation 6 8
Number of prior chemotherapy
cycles (Median, Mean, SD)
8.5, 8.6, 4.1 9, 7.8, 3.2 0.68Target CD34 count in the final
product of collection
(Median, Mean, SD)3, 4, 1.55 3, 4, 1.45 0.72127
IMPROVING AUTOLOGOUS TRANSPLANT OUTCOMES IN THE ELDERLY
Parikh, J.R., Kota, V., Awan, F.T., Jillella, A.P. Medical College of
Georgia, Augusta, GA
Introduction: High dose chemotherapy and autologous stem cell
transplant (HD-SCT) improve disease free (DFS) and overallsurvival (OS) and can be curative in various hematologic malignan-
cies. HD-SCT is also associated with significant morbidity and
hence is not routinely offered to elderly patients.
Methods: In this study we describe our experience in patients aged
70 years or above who underwent HD-SCT between 2000 and 2010.
Data was collected from retrospective review of our transplant regis-
try and medical records and was analyzed utilizing SPSS v13.
Results: Twenty patients aged 70 years or above underwent HD-
SCT for a variety of hematologic malignancies (10 patients with
Multiple Myeloma, 9 with Non-Hodgkin Lymphoma and 1 with
Hodgkin Lymphoma). Median age of the patients was 71 years
(range 70-76). All patients had a good performance status (median
ECOGPS was 1, range 0-1) at the time of transplant. 80% of the pa-
tients were males and 60% were in a complete remission at the time
of transplant. Conditioning was with BEAM for NHL and HL pa-
tients (20% required dose adjustment due to co-morbid conditions)
andMelphalan forMMpatients (20% received 140mg/m2 due to re-
nal function). The mean CD34 cells collected was 7.5x106 cells/kg
and the number infused was 5.54 x106 cells/kg. All patients engrafted
and the median number of days for neutrophil engraftment was 10
and for platelets was 12. Overall the transplant process was well tol-
erated with mucositis being the most common complication seen in
40% of the patients (grades 1-3). Other complications included diar-
rhea (10% grade 1-2 and 20% grade 3-4), febrile neutropenia (20%
grade 3-4), sepsis (15% grade 3-4) and atrial fibrillation (10% grade
1-2). The estimated 5-year overall survival is 56.7% and 5-year
progression free survival is 55.4%. There were no deaths during
the immediate transplant process.
Conclusions: Our data suggests that in a well-selected elderly pop-
ulation older than 70 years HD-SCT appears to be a well tolerated
therapeutic option. We therefore recommend that age should not
be utilized as sole exclusion criteria for patients undergoing HD-
SCT for their various hematologic malignancies.128
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Preclinical and non-transplant clinical data indicates synergism be-
tween melphalan and bortezomib with enhanced melphalan-induced
DNA damage via bortezomib-mediated down regulation of Fanconi
anemia (FA)/BRCA DNA repair pathway. We designed a trial to ex-
amine the sequencing of high dose melphalan (100 mg/m2/day  2
days), immediately followed by one dose of bortezomib (0.7, 1.0, or
1.3 mg/m2 on a phase I study design) and tandem autologous trans-
plants. Thirty patients with primary refractory multiple myeloma or
plasma cell leukemia were treated between 05/2005 and 02/2009.
The patients received 2 cycles of preconditioning bortezomib (1. 3
mg/m2) and proceeded with transplants. The median age was 54.5
years (range, 36 – 70 years). The median beta 2-microglobulin was
4.35 mg/L (range: 1.8-11.4); albumin was 3.7 g/dL (range: 3.1-4.9).
Preconditioning bortezomib resulted in 1 complete response (CR), 1
very good partial response (VGPR), 9 partial response (PR), 13 stable
disease (SD), 3 progressive disease (PD) and 3 patients were not evalu-
able. The overall response rate (ORR) was 36%. A total of 25 patients
proceeded with transplants. By 90 days, we documented 5 CR, 6
VGPR, 10 PR and 1 SDpost tandem transplants. TheORR increased
to 84% at the peak of best response with 9 CR, 3 VGPR, and 9 PR.
With a median follow-up of 24.5 months (range, 3 – 62 months), the
median progression-free survival from the first dose of bortezomib
was 15 months (95% CI: 11 – 20 months) and the median overall
Poster Session I S201survival was 35months (95%CI: 22 – 43months). There were nodose
limiting toxicities. Grade 3 toxicities were similar to those observed
withhigh dosemelphalan alone.The dose of bortezomib administered
after melphalanwas safely escalated to 1.3mg/m2. FA/BRCA pathway
gene expression was evaluated with quantitative RT-PCR (i) at base-
line, (ii) after 1 dose of bortezomib, and (iii) after the 2 pre-transplant
cycles of bortezomib in 17 patients (15 had transplants). After the first
dose of bortezomib, there was a statistically significant decreased ex-
pression of FANCD1 (P 5 0.072) and FANCF (P 5 0.0458) as well
as a suggestion of decreased expression of 4 other FA/BRCA genes.
We conclude that bortezomib can be safely combined with high
dose melphalan and with no added toxicity. The combination of bor-
tezomib and melphalan conditioning warrants further evaluation
with a phase 2 study design in a broader myeloma population.129
PROLIFERATIVE CAPACITY AND CELLULAR COMPOSITION OF APHERE-
SIS PRODUCTS COLLECTED FROM PATIENTS MOBILIZED SEQUENTIALLY
WITH NEUPOGEN THEN NEUPOGEN PLUS PLERIXAFOR
Siebenlist, R., Sawyer, S., Taylor, R., Treisman, J., Garlie, N. Aurora St.
Luke’s Medical Center, Milwaukee, WI
Background: Mobilization with Neupogen plus Plerixafor versus
Neupogen alone yields a product with more CD341 stem cells,
thus reducing the overall time and cost for stem cell collections.
Since the mechanism of action is different for these two mobilizing
agents, we determined whether or not there are differences in the
proliferative potential and cellular composition of the apheresis
products collected after mobilization.
Methods:Wecompared apheresis products frompatientsmobilized
with both stem cell regimens sequentially (Neupogen only, then
Neupogen plus Plerixafor). Stem cells (CD45/34) were enumerated
prior to cryopreservation by flow cytometry.The proliferative capac-
ity of thawed apheresis products was evaluated using a HALO assay
(Hemogenix), which utilizes luminescence to measure the prolifera-
tive capacity of cells by quantifyingATP concentrations.The cellular
composition of the thawed samples was evaluated by flow cytometry
for various lineage markers and T-cell differentiation markers.
Results: The proliferative capacity of apheresis products collected
after mobilization with Neupogen was lower compared to products
collected after Neupogen plus Plerixafor mobilization (p\ 0.05).
This correlates with the CD34 content in the products, which tends
to be lower in products mobilized with Neupogen (0.2560.18%)
versus Neupogen plus Plerixafor (0.3560.27%), but the difference
is not significant (p 5 0.23). However, ATP levels calculated per
stem cell were similar (P 5 0.34, n 5 15 patients) between products
mobilized with the two regimens. Phenotypic analyses of the prod-
ucts from 3 patients each mobilized with both regimens were
performed. T-helper cells (CD4) were higher (32% vs. 24%, P 5
0.02) in the apheresis productsmobilizedwithNeupogen only versus
Neupogen plus Plerixafor. There were no other significant differ-
ences in phenotypic markers, however, there was a trend toward
a lower percentage of lin1dimHLA-DR1CD11c1 dendritic cells
(p5 0.08) in the apheresis productsmobilizedwithNeupogen versus
Neupogen plus Plerixafor. Evaluation of additional samples will
determine if this trend is significant.Table 1. Outcomes of Autologous PBSC Mobilization with G-CSF a
with or without Lenalidomide (LEN)
L
All (n517) #4
Day 1 CD34+ cells/mL, median (range) 75.83 (12.46-167.37) 73.57
Day 1 CD34+ cell yield (x 106/kg), median (range) 4.96 (1.43-17.11) 6.87
Total CD34+ cell yield (x 106/kg), median (range) 7.22 (2.32-17.11) 6.87
CD34+ cell yield $6  106/kg, no. of patients (%)
Day 1 8 (47.1) 5
All days 11 (64.7) 5
*All LEN-treated patients vs. no LEN;
**2-sided Mann-Whitney U test;
†2-sided Fisher exact testConclusion: Although the mechanisms of action of Neupogen and
Plerixafor are different, the proliferative capacity of the stem cells
generated after treatment with Neupogen alone versus Neupogen
plus Plerixafor is similar. However, the cellular composition of the
products is different and may affect the quality of the stem cell graft.130
INITIAL MOBILIZATION OF AUTOLOGOUS PERIPHERAL BLOOD STEM
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PATIENTS
Anwer, F., Green, M.R., Yeager, A.M. Arizona Cancer Center, Univer-
sity of Arizona, Tucson, AZ
Background: The use of lenalidomide (LEN) in patients (pts) with
multiple myeloma (MM) is associated with impaired mobilization
and collection of autologous peripheral blood stem cells (PBSCs) af-
ter granulocyte colony-stimulating factor (G-CSF) or chemotherapy
plus G-CSF. The combination of G-CSF and plerixafor (PLX; Mo-
zobil) is an evolving strategy for PBSC mobilization, but effects of
LEN exposure on mobilization with G-CSF and PLX have not been
extensively evaluated. This single-center prospective study com-
pared results of initial PBSC mobilization with G-CSF and PLX
in MM pts whose primary therapy did or did not include LEN.
Patients andMethods:Of 23 consecutive pts, 17 had received ame-
dian of 5 (range 2-12) 21-day cycles of LEN; 6 had not received
LEN. All pts received G-CSF (10 mg/kg/day sq  4 days) and
PLX (0.24 mg/kg sq on the evening of 4th day of G-CSF), with first
apheresis (3 blood volume) at amedian of 16.6 (range 15.3-17.5) hr
after PLX injection. Pts who collected\ 6  106/kg CD341 cells
with first apheresis received both G-CSF and PLX that evening
and underwent a second day of apheresis. Mobilization failure was
defined as total collection of\2 x106/kg CD341 cells; optimal col-
lection was defined as $ 6  106/kg CD341 cells.
Results: All 17 LEN-treated pts collected $ 2  106/kg CD341
cells (median 7.22  106/kg; range 2.32-17.11  106/kg) with a me-
dian of 2 (range 1-3) aphereses. Eleven pts (64.7%) collected $ 6 
106/ kgCD341 cells, 8 with 1 apheresis. Five of 8 pts who received#
4 cycles of LEN collected$ 6 106/ kg CD341 cells with 1 apher-
esis, compared with 3 of 9 pts who received. 4 cycles (P5 0.35). All
6 pts without LEN collected $ 6  106/kg CD341 cells (median
13.67  106/kg; range 6.56-22.66  106/kg) with a median of 1
(range 1-2) apheresis. The LEN group had lower median day 1 pe-
ripheral blood CD341 cell levels (75.83 vs. 135.00/mL; P 5 0.052),
day 1 apheresis yields (4.96 vs. 13.67  106/kg CD341 cells; P 5
0.030) and total apheresis yields (7.22 vs. 13.67  106/kg CD341
cells; P 5 0.024) than the non-LEN group.
Conclusions: Initial mobilization with G-CSF and PLX is effective
in LEN-treated MM pts, with a trend to more robust day 1 PBSC
collections after# 4 cycles of LEN. In this prospective comparison,
however, the outcomes in LEN-treated pts were inferior to those in
pts without LEN exposure. Additional studies are needed to delin-
eate the influence of LEN on mobilization of PBSCs with G-CSF
and PLX.nd Plerixafor in Multiple Myeloma Patients Previously Treated
EN-treated
cycles (n58) >4 cycles (n59) No LEN (n56) P*
(12.46-167.37) 50.68 (26.24-163.08) 135.00 (52.56-222.84) 0.052**
(1.43-17.11) 4.14 (2.26-14.19) 13.67 (4.16-22.66) 0.030**
(2.32-17.11) 6.20 (4.15-14.19) 13.67 (6.56-22.66) 0.024**
(62.5) 3 (33.3) 5 (83.3) 0.18†
(62.5) 6 (66.7) 6 (100) 0.14†
